Prospects for the approval of this Drug in USA looks very good for 2012. AXN has recently arranged financing for 2012. They have a lot going for them for such a small R&D company. They have modern facilities and relationships with strong Pharmaceutical companies. I feel that this company is excellent value and not a sham. Management is committed to make this company a success.